360 High-Risk Vulnerability Immunization Tool V2.0 vs Ivanti Neurons for App Control: Side-by-Side Comparison (2026)

360 High-Risk Vulnerability Immunization Tool V2.0: Tool that immunizes Windows systems against critical vulnerabilities. built by 360 Security Group (Qihoo 360). Core capabilities include Remote desktop vulnerability immunization (CVE-2019-0708, CVE-2019-1181, CVE-2019-1182), MS17-010 SMB vulnerability protection against ransomware, Meltdown CPU vulnerability mitigation..

Ivanti Neurons for App Control: Application control and privilege management for endpoint security. built by Ivanti. Core capabilities include Trusted ownership-based application control using NTFS security, Privilege management for application-specific admin rights elevation, Granular allow and deny rules for application access control..

Both serve the Endpoint Protection Platform market but differ in approach, feature depth, and target audience.

360 High-Risk Vulnerability Immunization Tool V2.0 differentiates with Remote desktop vulnerability immunization (CVE-2019-0708, CVE-2019-1181, CVE-2019-1182), MS17-010 SMB vulnerability protection against ransomware, Meltdown CPU vulnerability mitigation. Ivanti Neurons for App Control differentiates with Trusted ownership-based application control using NTFS security, Privilege management for application-specific admin rights elevation, Granular allow and deny rules for application access control.

360 High-Risk Vulnerability Immunization Tool V2.0 is developed by 360 Security Group (Qihoo 360). Ivanti Neurons for App Control is developed by Ivanti. Vendor maturity, funding stage, and team size can be important factors when evaluating long-term viability and support quality.

360 High-Risk Vulnerability Immunization Tool V2.0 and Ivanti Neurons for App Control serve similar Endpoint Protection Platform use cases: both are Endpoint Protection Platform tools, both cover Zero Day, Windows Security. Review the feature comparison above to determine which fits your requirements.